ClinicalTrials.gg

Program

Goserelin

Also written as “Goserelin acetate”, “ZOLADEX” and “Inj. Goserelin (Test) Subcutaneously”.

Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Metrorrhagia, led by 4 companies.

Furthest: phase 4, since Oct 26, 200512 company-led studies, 1 open or runningNext primary completion: Mar 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca80 open or runningphase 4since Oct 26, 2005Oct 10, 2005none ahead
Eurofarma Laboratorios20 open or runningphase 3since Apr 29, 2019Apr 29, 2019none ahead
Peptigroupe10 open or runningphase 1since Jun 9, 2020Jun 9, 2020none ahead
TerSera Therapeutics11 open or runningphase 1since Dec 16, 2025Dec 16, 2025Mar 30, 2027phase 1 · NCT07310420

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2005First study: phase 2 study in Breast NeoplasmsNew to AstraZenecaAstraZeneca · NCT00235937 · 45 enrolled · France
  2. Oct 26, 2005Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00255268 · 15 enrolled · Mexico
  3. Mar 16, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00303524 · 170 enrolled · Japan
  4. May 3, 2006Phase 2 study in NeoplasmsAstraZeneca · NCT00322348 · 98 enrolled · Czech Republic, Russian Federation, Ukraine
  5. Apr 23, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00888082 · 102 enrolled · Turkey
  6. Feb 22, 2010Phase 3 study in Breast NeoplasmsAstraZeneca · NCT01073865 · 222 enrolled · India, Japan, Korea, Republic of and more
  7. Jun 27, 2018Phase 3 study in Breast NeoplasmsAstraZeneca · NCT03658213 · China
  8. Mar 21, 2019Phase 4 study in Advanced Prostate CancerAstraZeneca · NCT03971110 · 9 enrolled · China
  9. Apr 29, 2019Eurofarma Laboratorios's first studies: 2 phase 3 studiesNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT03936933, NCT03936218
  10. Jun 9, 2020Peptigroupe's first study: phase 1 study in MetrorrhagiaNew to PeptigroupePeptigroupe · NCT04428684 · 80 enrolled · Ukraine
  11. Dec 16, 2025TerSera Therapeutics's first study: phase 1 study in Breast NeoplasmsNew to TerSera TherapeuticsTerSera Therapeutics · NCT07310420 · 176 planned · United States

Ahead

  1. Mar 30, 2027Primary completion: phase 1 study in Breast NeoplasmsTerSera Therapeutics · NCT07310420

TargetBeta

GNRH1 →GNRHR →read by rule
“A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
triptorelinruleIpsenphase 421

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07310420Breast Neoplasms · United States1RecruitingTerSera TherapeuticsMar 30, 2027176
NCT04428684Metrorrhagia · Ukraine1CompletedPeptigroupeApr 1, 202080
NCT03936933Breast Neoplasms · India3TerminatedEurofarma LaboratoriosSep 30, 20246
NCT03936218Advanced Prostate Cancer · India3CompletedEurofarma LaboratoriosNov 30, 202394
NCT03971110Advanced Prostate Cancer · China4TerminatedAstraZenecaNov 9, 20229
NCT03658213Breast Neoplasms · China3WithdrawnAstraZenecaNov 4, 20210
NCT01073865Breast Neoplasms · India, Japan, Korea, Republic of and more3CompletedAstraZenecaSep 19, 2012222
NCT00888082Breast Neoplasms · Turkey3WithdrawnAstraZenecaApr 2012102
NCT00322348Neoplasms · Czech Republic, Russian Federation, Ukraine2CompletedAstraZeneca98
NCT00303524Breast Neoplasms · Japan2CompletedAstraZenecaAug 2007170
NCT00255268Prostatic Neoplasms · Mexico4WithdrawnAstraZeneca15
NCT00235937Breast Neoplasms · France2CompletedAstraZeneca45

How it is read

Names in the registry

  • “Goserelin acetate”, 5 entries
  • “Goserelin”, 2 entries
  • “ZOLADEX”, 1 entry
  • “Inj. Goserelin (Test) Subcutaneously”, 1 entry
  • “Goserelin acetate 3.6 mg Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.